10.1016j.jtho.2016.11.2228.ann

T1 Level 1094 1104 tumor cell
T2 Level 1552 1563 tumor cells
T3 Condition 308 313 tumor
T4 Biomarker 1280 1285 PD-L1
T5 Condition 299 314 39 NSCLC tumors
T6 Condition 856 861 tumor
T7 Biomarker 53 58 PD-L1
T8 Condition 1552 1557 tumor
T9 Protein 379 384 SP263
T10 Biomarker 1891 1896 PD-L1
T11 Level 1020 1031 immune cell
T12 Condition 1665 1670 tumor
T13 Protein 944 949 SP142
T14 Protein 908 913 SP263
T15 Level 1665 1675 tumor cell
T16 Protein 1886 1887 ”
T17 Organism 1913 1921 patients
T18 Level 980 991 tumor cells
T19 Level 1604 1615 immune cell
T20 Level 842 867 PD-L1–stained tumor cells
T21 Biomarker 1389 1394 PD-L1
T22 Level 526 537 immune cell
T23 Biomarker 1786 1791 PD-L1
T24 Level 526 538 immune cells
T25 Organism 1913 1920 patient
T27 Protein 1868 1869 “
T28 Condition 980 985 tumor
T29 Level 980 990 tumor cell
T30 Level 1487 1497 tumor cell
T31 Biomarker 842 847 PD-L1
T32 Condition 516 521 tumor
T33 Level 1552 1562 tumor cell
T34 Level 856 866 tumor cell
T35 Condition 1487 1492 tumor
T36 Biomarker 338 343 PD-L1
T37 Biomarker 2052 2057 PD-L1
T38 Protein 368 373 SP142
T39 Organism 643 650 patient
T40 Condition 1094 1099 tumor
T41 Biomarker 240 245 PD-L1
R1 Relation Arg1:T36 Arg2:T9
R2 Relation Arg1:T36 Arg2:T38